Alnylam Pharmaceuticals company profile

ALNY · NASDAQ · USD

Compare Alnylam Pharmaceuticals
$156.50Change from previous close: −2.02%Absolute change: −$3.23

Close · November 17, 2026

Company profile

Alnylam Pharmaceuticals has 2,500 employees and is headquartered in Cambridge, United States.

Alnylam's customers are patients with rare and chronic diseases in the United States, Europe and other international markets, where its RNA interference therapies are sold for conditions such as transthyretin amyloidosis, hypercholesterolemia, hemophilia and primary hyperoxaluria type 1. Its marketed medicines include ONPATTRO, AMVUTTRA, Leqvio, Qfitlia, GIVLAARI and OXLUMO, while its pipeline spans cardiovascular, metabolic, liver, neurological and hematological diseases, with several candidates in Phase 3 trials. The company develops, manufactures and commercializes these therapies and works with partners including Regeneron, Roche, Sanofi and Novartis.

In the fiscal year ended December 2025, Alnylam reported revenue of $3.7 billion, up 65.2% from the previous year, and net income of $313.7 million. The company had 2,500 employees and is headquartered in Cambridge, Massachusetts, where it was founded in 2002.

Company facts

Industry
Biotechnology
Headquarters
675 West Kendall Street, 02142, Cambridge
Employees
2,500
Chief executive
Yvonne Greenstreet
Founded
2002
Fiscal year
January - December
Listing
ALNY · NASDAQ
Indices
Nasdaq 100
Currency
USD
ISIN
US02043Q1076

Alnylam Pharmaceuticals and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Alnylam PharmaceuticalsALNYUnited States$22.11B2,50019.5%8.34
BioNTechBNTXUnited States$21.22B7,807-55.4%—
IncyteINCYUnited States$24.36B2,84432.2%61.0
InsmedINSMUnited States$26.96B1,664-41.7%—
Ascendis PharmaASNDUnited States$18.06B1,18930.9%18.1
Roivant SciencesROIVUnited States$28.64B721-3,226.3%—

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Alnylam Pharmaceuticals with its competitors